Development and Validation of an LC-MS/MS Method for the Quantitation of JNJ-64619178 (JNJ) in Mouse Plasma:
Nusrat Ahmed1, Pratiksha Kshirsagar1, Ling Ding1
1Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Abstract:
Overexpression of protein arginine methyltransferase 5 (PRMT5) is pivotal in MYC-driven primary medulloblastoma tumors, suggesting PRMT5 as a potential therapeutic target. JNJ, a potent PRMT5 inhibitor currently in clinical trials, notably for non-Hodgkin lymphoma and lung cancer, was evaluated in this study. We report a validated LC-MS/MS bioanalytical method for quantifying JNJ in plasma and tissue matrices. The method demonstrated acceptable sensitivity, selectivity, and robustness in accordance with regulatory guidelines. The assay was linear over the range 0.2-500 ng mL-1 (r2 = 0.99), with plasma recovery exceeding 84% using only 100 µL of sample. Precision (%RSD < 15%) and accuracy (~91-108%) were within acceptable limits. JNJ showed >94% plasma protein binding and moderate Caco-2 permeability (3.4 ± 0.4 × 10-6 cm s-1). Hepatic intrinsic clearance was higher in mouse liver microsomes than in human (41 ± 19 vs. 7 ± 0.6 mL min-1 kg-1). Following oral dosing in mice (10 mg kg-1), Tmax was 30 min with a Cmax of 2781 ± 1033 ng mL-1. Oral bioavailability was low (15%). The validated method was successfully applied to in vitro and in vivo studies and will guide dosing in animal models of medulloblastoma.
Insights
Protein arginine methyltransferase 5 (PRMT5) inhibition is key for treating MYC-driven medulloblastoma. A PRMT5 inhibitor, JNJ, was analyzed using a validated LC-MS/MS method, showing its pharmacokinetic profile in preclinical studies.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Protein arginine methyltransferase 5 (PRMT5) overexpression drives MYC-driven medulloblastoma.
- PRMT5 is a potential therapeutic target for medulloblastoma.
- JNJ is a PRMT5 inhibitor investigated in clinical trials for other cancers.
Purpose of the Study:
- To develop and validate a bioanalytical method for quantifying JNJ in plasma and tissue.
- To characterize the pharmacokinetic properties of JNJ in preclinical models.
- To support in vitro and in vivo studies of JNJ in medulloblastoma.
Main Methods:
- Liquid chromatography-tandem mass spectrometry (LC-MS/MS) for bioanalysis.
- Assay validation for sensitivity, selectivity, linearity, precision, and accuracy.
- Pharmacokinetic studies including protein binding, Caco-2 permeability, hepatic clearance, and oral dosing in mice.
Main Results:
- A validated LC-MS/MS method quantified JNJ in plasma and tissue with high linearity (r² = 0.99) and accuracy (91-108%).
- JNJ exhibited >94% plasma protein binding, moderate Caco-2 permeability, and higher hepatic clearance in mice than humans.
- Oral administration in mice resulted in low bioavailability (15%) and a Tmax of 30 min.
Conclusions:
- A robust bioanalytical method for JNJ was established, suitable for preclinical research.
- JNJ demonstrates specific pharmacokinetic characteristics that warrant further investigation for medulloblastoma treatment.
- The validated method will guide future dosing strategies in medulloblastoma animal models.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
08:24Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS
Published on: January 23, 2026
Related Concept Videos
Measurement of Bioavailability: Pharmacodynamic Methods
Measurement of Bioavailability: Pharmacokinetic Methods
Drug Product Performance: In Vitro–In Vivo Correlation
Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
Drug Concentrations: Measurements
Plasma —...
